<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964873</url>
  </required_header>
  <id_info>
    <org_study_id>9090-04</org_study_id>
    <nct_id>NCT00964873</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synta Pharmaceuticals Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synta Pharmaceuticals Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090
      (ganetespib) in subjects with AML, ALL and blast-phase CML.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess efficacy in subjects with AML, ALL and blast-phase CML based on standard response criteria</measure>
    <time_frame>every 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the safety and tolerability of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML</measure>
    <time_frame>ongoing</time_frame>
    <description>as per adverse event and serious adverse event reporting</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Blast-phase Chronic Myelogenous Leukemia</condition>
  <condition>AML</condition>
  <condition>ALL</condition>
  <condition>CML</condition>
  <arm_group>
    <arm_group_label>1 Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STA-9090 (ganetespib)</intervention_name>
    <description>Chemotherapy agent</description>
    <arm_group_label>1 Part 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a pathologic confirmation of the diagnosis of AML, ALL, or blast-phase
             CML

          -  ECOG Performance Status 0-2

          -  Adequate organ function as defined in the protocol.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Hyperleukocytosis

          -  Acute Promyelocytic Leukemia (FAB-M3) subtype

          -  Uncontrolled Disseminated Intravascular Coagulation (DIC)

          -  Active central nervous system leukemia

          -  Concomitant radiation therapy, chemotherapy, or immunotherapy

          -  Women who are pregnant or lactating

          -  Neuropathy â‰¥ grade 2 (NCI CTCAE) at time of enrollment

          -  Chemotherapy (with the exception of hydroxyurea) or radiotherapy within two weeks or
             within six times the agent's half life

          -  Require ongoing therapy with either G- or GM-CSF, or long-acting versions of these
             molecules

          -  Use of any investigational agents within two weeks or within six times the agent's
             half life --Treatment with chronic immunosuppressants

          -  Other medical/psychiatric condition that may increase the risk associated with study
             participation as defined by the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>September 17, 2014</last_update_submitted>
  <last_update_submitted_qc>September 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Synta</keyword>
  <keyword>STA-9090</keyword>
  <keyword>ganetespib</keyword>
  <keyword>Hematologic Cancers</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Blast-phase Chronic Myelogenous Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>CML</keyword>
  <keyword>HSP90 Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

